PATENT CLAIM ANALYSIS

Application Number: 16140964
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-05
Patent Classification: ["552", "500000"]

Abstract:
5-cholesten, 3β, 25-diol, disulfate (25HCDS) has been found to be an authentic PPAR γ  agonist and LXR antagonist, and is used for the therapy of lipid disorders and inflammatory diseases, including without limitation fatty liver, inflammatory bowel, and atherosclerotic diseases.

Claim (Index 5):
A method of treating a subject, which method comprises administration to the subject of an effective amount of a compound as defined in  claim 1 , wherein said method is selected from: a method for reducing lipids in a subject in need thereof; a method of reducing cholesterol and lipid biosynthesis in a subject in need thereof; a method of reducing inflammation in a subject in need thereof; a method of treating diabetes in a subject in need thereof; a method of treating hyperlipidemia in a subject in need thereof; a method of treating atherosclerosis in a subject in need thereof; a method of treating fatty liver disease in a subject in need thereof; and a method of treating inflammatory disease in a subject in need thereof.

Metadata:
- Claim Count in Document: 48.0
- Percentile: 97.0
- Lexical Diversity: 1.28205
- Patent Class: 552.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['12708803', '15042244', '13766839', '13441241', '14689822']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6759257307057442
- 35 USC 102 Novelty (BERT): 0.5998868153145416
- Combined Prediction Score: 0.668321839166624
- Mean Citation Score: 306.00344
- Max Citation Score: 331.9455
- Similarity Product: 236.5893531065583

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test